PolyPid’s D-PLEX100 and PLEX Technology: A Promising Buy Amidst Upcoming Phase 3 SHIELD II Trial

PolyPid (PYPD) has received a new Buy rating, initiated by Rodman & Renshaw analyst, Brandon Folkes.

Brandon Folkes has given his Buy rating due to a combination of factors related to PolyPid’s innovative PLEX technology and its lead product, D-PLEX100. The company is valued primarily on D-PLEX100, which is designed to prevent surgical site infections by providing localized and prolonged delivery of doxycycline. Despite the market’s cautious approach, Folkes sees significant potential in the product, especially with the upcoming Phase 3 SHIELD II trial results expected in the second quarter of 2025.
Folkes believes that the current enterprise value of PolyPid presents a favorable risk/reward scenario, as success in the SHIELD II trial could lead to substantial revenue generation, potentially exceeding the $11 price target. Even if the trial does not meet expectations, the broader PLEX platform still holds value, as evidenced by existing partnerships. The decision to increase the trial size to 800 patients suggests a positive efficacy signal, reinforcing confidence in the PLEX technology’s capability to effectively deliver drugs and providing a valuation floor for the stock.